cjc-1295 no dac vs tesamorelin

At a glance: The short version

In preclinical model comparisons between CJC-1295 No DAC vs Tesamorelin, both peptides function as synthetic growth hormone-releasing hormone (GHRH) receptor agonists, yet they present key structural and kinetic variations. CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino-acid peptide modified at four positions to extend plasma half-life to approximately 30 minutes, producing natural, physiological GH spikes when co-administered in vitro or in vivo with GHRPs.

Tesamorelin is a 44-amino-acid peptide stabilized with a hexenoyl group at its N-terminus. It exhibits higher specificity for visceral adipose tissue lipolysis models while driving robust GH and downstream IGF-1 expression. While both compounds avoid the continuous, non-pulsatile GH elevation seen in Drug Affinity Complex (DAC) variants, Tesamorelin demonstrates distinct pharmacokinetic stability in metabolic research protocols.

When sourcing high-purity peptides for comparative assays, investigators rely on PX1 Research for verified lot traceability. You can explore our catalog of research peptides or directly view individual product specifications on our live catalog pages.

What is CJC-1295 No DAC? Sequence and mechanism

CJC-1295 No DAC, commercially and scientifically recognized as Modified GRF 1-29, is a truncated tetrasubstituted analog of endogenous GHRH. Endogenous GHRH is rapidly cleaved by the enzyme dipeptidyl peptidase IV (DPP-IV) at the Ala2 position, yielding an active biological half-life of less than 10 minutes. Modified GRF 1-29 replaces native amino acids at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27), granting resistance to enzymatic hydrolysis.

This structural stabilization extends the half-life to approximately 30 minutes in mammalian plasma models without altering receptor affinity. By preserving the short clearance window, CJC-1295 No DAC allows researchers to simulate natural, pulsatile growth hormone secretion from pituitary somatotrophs.

In laboratory models evaluating tissue repair and muscle protein synthesis, researchers often pair this peptide with selective GH secretagogues. Lab managers looking to source high-grade material can order 5mg vials of CJC-1295 No DAC directly from PX1 Research.

What is Tesamorelin? Structure and physiological targets

Tesamorelin is a synthetic 44-amino-acid peptide that represents a modified full-length structure of human GHRH. Its chemical design features a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue. This lipophilic modification significantly retards DPP-IV cleavage, allowing the molecule to remain stable in systemic circulation longer than native GHRH.

Preclinical data indicate that Tesamorelin selectively stimulates pituitary somatotrophs to synthesize and release growth hormone, which subsequently triggers hepatic synthesis of Insulin-like Growth Factor 1 (IGF-1). A defining characteristic of Tesamorelin in published research is its marked affinity for altering lipid metabolism and deep visceral adipose tissue accumulation in rodent and clinical assay models.

Due to its high specificity and stability, researchers often select this sequence for metabolic rate, lipid oxidation, and tissue regeneration research. Qualified laboratories can purchase 10mg vials of Tesamorelin backed by lot-specific analytical documentation.

Receptor activation and downstream signaling mechanisms

Both CJC-1295 No DAC and Tesamorelin bind to the G-protein coupled GHRH receptor (GHRHR) located on pituitary somatotroph membranes. Upon ligand binding, the receptor undergoes a conformational change that activates the intracellular Gs alpha subunit. This stimulation triggers adenylyl cyclase, accelerating the conversion of ATP to cyclic adenosine monophosphate (cAMP).

Elevated intracellular cAMP activates protein kinase A (PKA), leading to the phosphorylation of CREB (cAMP response element-binding protein) and the influx of extracellular calcium via voltage-gated ion channels. This cascade induces immediate exocytosis of stored GH granules into the extracellular space.

The primary difference in signaling duration stems from molecular structure. While CJC-1295 No DAC generates a clean, sharp pulse that returns to baseline rapidly, Tesamorelin demonstrates sustained signaling per receptor engagement event, resulting in higher cumulative AUC (area under the curve) for growth hormone output during comparative trial periods.

Comparing CJC-1295 No DAC vs Tesamorelin: Key criteria

To assist laboratory personnel in protocol selection, the following criteria highlight the primary biochemical and logistical differences between CJC-1295 No DAC and Tesamorelin:

- Amino Acid Length: CJC-1295 No DAC features 29 amino acids; Tesamorelin features 44 amino acids plus an N-terminal hexenoyl group. - Resistance to DPP-IV: CJC-1295 No DAC uses amino acid substitutions (D-Ala2); Tesamorelin utilizes N-terminal fatty acid conjugation. - Biological Half-Life: CJC-1295 No DAC exhibits a half-life of ~30 minutes; Tesamorelin exhibits a half-life of ~26–38 minutes with distinct hepatic clearance dynamics. - Research Focus: CJC-1295 No DAC is typically evaluated for systemic protein synthesis, tissue repair, and ghrelin-mimetic synergy; Tesamorelin is primarily studied for visceral adiposity reduction, hepatic lipid clearance, and neuroprotective pathways. - Pulsatile vs Baseline: Both preserve pulsatile GH release, unlike long-acting CJC-1295 DAC which causes continuous basal GH elevation. - Purity Standard: PX1 Research guarantees ≥99.0% peptide purity for both compounds via RP-HPLC analysis.

Investigators seeking technical documentation on additional GHRH analogs can reference our detailed technical articles in the PX1 Research library.

Purity criteria and analytical standards comparison

Evaluating research peptides requires rigorous verification of molecular identity and purity. Inferior synthesis processes can leave trifluoroacetic acid (TFA) salts, truncated peptide sequences, or heavy metals that skew experimental outcomes and cause cellular toxicity in cell culture assays.

PX1 Research enforces strict analytical standards across every production batch. The table below illustrates how PX1 Research metrics compare to standard market vendors:

How to reconstitute and store GHRH analogs in vitro

Proper handling and storage of lyophilized peptides are critical to maintaining structural integrity and preventing enzymatic degradation. Lyophilized CJC-1295 No DAC and Tesamorelin are delivered as highly stable cakes, but proper reconstitution protocols must be followed in laboratory settings.

1. Temperature Verification: Store dry lyophilized vials at -20°C prior to reconstitution. Allow the vial to reach room temperature before adding solvents to prevent condensation accumulation. 2. Solvent Selection: Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline depending on assay requirements. 3. Reconstitution Technique: Gently direct the diluent down the glass wall of the vial. Do not squirt liquid directly onto the lyophilized powder cake. Gently swirl the vial in a circular motion; never shake or vortex peptide solutions, as mechanical shear forces can denature delicate secondary peptide structures. 4. Aliquoting and Storage: Once reconstituted, store solution at 2°C to 8°C for short-term assays (up to 30 days). For long-term preservation, aliquot into single-use polypropylene tubes and store at -80°C to eliminate repeated freeze-thaw cycles.

To maintain seamless experimental supply lines, laboratories purchasing bulk quantities can review our flexible terms through the PX1 Research wholesale page.

Red flags when sourcing synthetic GHRH peptides

The market for research chemicals contains significant quality variations. Unregulated suppliers often sacrifice quality control to lower production costs, supplying researchers with compromised compounds. When selecting a vendor for CJC-1295 No DAC or Tesamorelin, watch for these common red flags:

First, beware of vendors providing non-batch-specific Certificates of Analysis. A COA must feature a batch number matching the physical vial received, complete with raw High-Performance Liquid Chromatography (RP-HPLC) chromatograms and Mass Spectrometry (MS) spectra showing correct mass determination.

Second, avoid suppliers operating without domestic US manufacturing oversight or clear endotoxin testing. High bacterial endotoxin levels (>0.05 EU/mg) alter cell culture viability and induce severe inflammatory responses in animal models, invalidating empirical data.

Third, avoid suppliers making illegal medical claims, human dosing recommendations, or therapeutic framing. Authentic research vendors operate strictly under laboratory research compliance protocols. PX1 Research adheres strictly to laboratory compliance standards, offering fully traceable, high-purity peptides intended solely for preclinical research.

Synergistic combinations and related growth secretagogues

In growth hormone axis studies, GHRH analogs are frequently paired with Growth Hormone Secretagogue Receptor (GHSR) agonists to analyze additive biological effects. While GHRH analogs like CJC-1295 No DAC amplify GHRHR signaling pathways, GHRPs trigger growth hormone release via distinct ghrelin-mediated pathways.

For instance, researchers frequently co-administer CJC-1295 No DAC alongside Ipamorelin to evaluate maximum peak GH release without inducing cortisol or prolactin spikes. Similarly, comparative protocols often examine Sermorelin, an earlier 29-amino-acid GHRH variant, to establish structural stability comparisons against newer modified molecules.

Reviewing the interaction of these distinct peptide families helps investigators design precise protocols for tissue regeneration, metabolic signaling, and pituitary response research.

Ordering from PX1 Research: Quality standards and logistics

When purchasing GHRH peptides for laboratory studies, PX1 Research provides an end-to-end supply chain designed for complete reliability and transparency. Every order dispatched from our US facilities comes with guaranteed batch purity and rapid fulfillment.

What ships with your order: Securely packaged, vacuum-sealed lyophilized peptide vials, accompanied by lot-matched digital documentation accessible directly through our site.

Available vial sizes: CJC-1295 No DAC is available in standard 2mg and 5mg vials; Tesamorelin is available in high-yield 5mg and 10mg research formats.

Same-day dispatch cutoffs: Orders placed before 3:00 PM EST (Monday through Friday) ship same-day directly from our primary distribution hubs in California and Arizona.

Tracked domestic transit: All orders include real-time tracking via expedited US carrier networks to minimize transit times and protect temperature-sensitive compounds.

COA Access: HPLC, MS, and endotoxin verification data are fully accessible per lot on demand.

Support responsiveness: Our technical support team consists of knowledgeable specialists ready to assist with order tracking, bulk procurement, and batch documentation queries.

To inspect inventory and place an order today, visit the main PX1 Research catalog.